References


11. Blevins T, Pieber TR, Vega GC, et al. Superior HbA1c reduction with basal insulin peglispro (BIL) vs. insulin glargine (GL) and preprandial insulin lispro in a double-blind study in patients (pts) with type 2 diabetes (T2D): IMAGINE 4. Diabetes. 2015;64(suppl 1):A250 [abstract 985-P].


19. Buse JB, Rodbard HW, Serrano CT, et al. Superior HbA1c reduction with basal insulin peglispro (BIL) vs. insulin glargine (GL) alone or with oral antihyperglycemic medications (OAMs) in T2D patients (pts) previously treated with basal insulin: IMAGINE 5 Diabetes. 2015;64(suppl 1):A249-A250 [abstract 984-P].


References (cont)


References (cont)


84. Marquez F, Brazg R, Christiansen M, et al. PE0139, the first recombinant fully human monomeric super-long-acting basal insulin to display a sustained nearly peakless insulin profile following a single subcutaneous dose in subjects with T2DM supporting weekly dosing. Diabetes. 2015;64(suppl 1):A26 [abstract 100-OR].


References (cont)


References (cont)


133. Wang H, Zhang Q, Frois C, et al. Safety and efficacy of insulin glargine 300 U/mL (Gla-300) compared with other basal insulin therapies in patients with type 2 diabetes mellitus (T2DM)—a network meta-analysis (NMA). Diabetes. 2015;64(suppl 1):A26 [abstract 99-OR].


